Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

被引：1078

作者：

Lombardo, LJ ^{[1
]}

Lee, FY ^{[1
]}

Chen, P ^{[1
]}

Norris, D ^{[1
]}

Barrish, JC ^{[1
]}

Behnia, K ^{[1
]}

Castaneda, S ^{[1
]}

Cornelius, LAM ^{[1
]}

Das, J ^{[1
]}

Doweyko, AM ^{[1
]}

Fairchild, C ^{[1
]}

Hunt, JT ^{[1
]}

Inigo, I ^{[1
]}

Johnston, K ^{[1
]}

Kamath, A ^{[1
]}

Kan, D ^{[1
]}

Klei, H ^{[1
]}

Marathe, P ^{[1
]}

Pang, SH ^{[1
]}

Peterson, R ^{[1
]}

Pitt, S ^{[1
]}

Schieven, GL ^{[1
]}

Schmidt, RJ ^{[1
]}

Tokarski, J ^{[1
]}

Wen, ML ^{[1
]}

Wityak, J ^{[1
]}

Borzilleri, RM ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 27期

关键词：

D O I：

10.1021/jm049486a

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent anti proliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

引用

页码：6658 / 6661

页数：4

共 12 条

[1] NEW METHODS FOR THE INTRODUCTION OF SUBSTITUENTS INTO THIAZOLES [J].

BEGTRUP, M ;

HANSEN, LBL .

ACTA CHEMICA SCANDINAVICA, 1992, 46 (04) :372-383

[2]

CHEN P, IN PRESS BIOORG MED

[3] Src in cancer: deregulation and consequences for cell behaviour [J].

Frame, MC .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2002, 1602 (02) :114-130

[4]

Huron DR, 2003, CLIN CANCER RES, V9, P1267

[5]

Lee FYF, 2001, CLIN CANCER RES, V7, P1429

[6]

Nagar B, 2002, CANCER RES, V62, P4236

[7] STI571 as a targeted therapy for CML [J].

O'Dwyer, ME ;

Mauro, MJ ;

Druker, BJ .

CANCER INVESTIGATION, 2003, 21 (03) :429-438

[8]

SAITO J, 1975, Patent No. 50089344

[9] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[10]

UENO K, 1968, Patent No. 43005394

← 1 2 →